Drug Profile


Alternative Names: ABX-CBL; Anti-CD147 monoclonal antibody ABX-CBL; CBL-1; Monoclonal antibody ABX-CBL; Monoclonal antibody CBL-1

Latest Information Update: 05 Apr 2006

Price : $50

At a glance

  • Originator Abgenix; CV Cancer Center
  • Developer Abgenix; SangStat
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Graft-versus-host disease; Psoriasis; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 21 Feb 2003 Data from a media release with results of a trial comparing gavilimomab with Atgam® for the treatment of steroid-resistant GVHD have been added to the Transplant Rejection therapeutic trials field
  • 18 Feb 2003 Discontinued for Renal transplant rejection in Japan (IV)
  • 18 Feb 2003 Discontinued - Phase-III for Graft-versus-host disease in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top